Profile data is unavailable for this security.
About the company
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes three clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, and a central nervous system (CNS)-penetrant EGFR inhibitor, and additional discovery-stage programs targeting other key oncogenic drivers. Its lead product candidate is naporafenib, a pan-RAF inhibitor with the potential for patients with NRAS-mutated (NRASm) melanoma, RAS Q61X solid tumors, and other RAS/MAPK pathway-driven tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-158.28m
- Incorporated2018
- Employees126.00
- LocationErasca Inc10835 Road To The Cure, Suite 140SAN DIEGO 92121-1130United StatesUSA
- Phone+1 (858) 465-6511
- Fax+1 (302) 636-5454
- Websitehttps://www.erasca.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ORIC Pharmaceuticals Inc | 0.00 | -110.78m | 677.91m | 107.00 | -- | 2.15 | -- | -- | -1.76 | -1.76 | 0.00 | 4.47 | 0.00 | -- | -- | 0.00 | -35.69 | -33.92 | -37.77 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
SS Innovations International Inc | 14.41m | -23.68m | 681.25m | 239.00 | -- | 40.11 | -- | 47.28 | -0.1396 | -0.1396 | 0.0847 | 0.0995 | 0.6003 | 2.28 | 5.08 | 60,293.01 | -98.66 | -161.38 | -216.15 | -449.76 | 28.42 | -79.79 | -164.35 | -495.77 | 0.9128 | -45.39 | 0.4172 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
Tourmaline Bio Inc | 0.00 | -35.69m | 685.39m | 44.00 | -- | 2.03 | -- | -- | -2.54 | -2.54 | 0.00 | 13.19 | 0.00 | -- | -- | 0.00 | -14.16 | -- | -14.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
Ironwood Pharmaceuticals, Inc. | 400.57m | 9.21m | 686.88m | 267.00 | 99.51 | -- | 74.49 | 1.71 | 0.0432 | 0.0432 | 2.43 | -2.01 | 0.8021 | -- | 4.52 | 1,500,244.00 | 1.44 | -4.54 | 2.21 | -5.20 | -- | -- | 1.79 | -7.81 | -- | 4.60 | 2.07 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
Mineralys Therapeutics Inc | 0.00 | -119.67m | 690.21m | 28.00 | -- | 2.38 | -- | -- | -2.71 | -2.71 | 0.00 | 5.84 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
Terns Pharmaceuticals Inc | 0.00 | -95.90m | 697.99m | 66.00 | -- | 2.66 | -- | -- | -1.31 | -1.31 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -36.84 | -41.34 | -38.72 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
Capricor Therapeutics Inc | 27.15m | -27.95m | 704.47m | 101.00 | -- | 60.20 | -- | 25.95 | -0.9302 | -0.9302 | 0.9072 | 0.3596 | 0.6443 | -- | 59.18 | 268,833.90 | -66.31 | -54.12 | -208.71 | -75.13 | -- | -- | -102.93 | -316.25 | -- | -- | 0.2269 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
Lenz Therapeutics Inc | 0.00 | -72.31m | 708.86m | 6.00 | -- | 3.45 | -- | -- | -9.45 | -9.45 | 0.00 | 7.46 | 0.00 | -- | -- | 0.00 | -29.53 | -- | -30.84 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
Erasca Inc | 0.00 | -158.28m | 717.56m | 126.00 | -- | 1.54 | -- | -- | -0.9207 | -0.9207 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -32.76 | -- | -34.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.50 | -- | -- | -- |
Arbutus Biopharma Corp | 10.06m | -77.09m | 724.92m | 73.00 | -- | 5.92 | -- | 72.05 | -0.4416 | -0.4416 | 0.0575 | 0.6488 | 0.0597 | -- | 4.59 | 137,821.90 | -45.77 | -52.62 | -53.21 | -58.11 | -- | -- | -766.20 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
AbCellera Biologics Inc | 33.06m | -153.30m | 736.66m | 586.00 | -- | 0.6631 | -- | 22.29 | -0.5254 | -0.5254 | 0.1133 | 3.77 | 0.0224 | -- | 0.808 | 56,407.85 | -10.39 | 6.08 | -11.11 | 6.67 | -- | -- | -463.77 | 24.69 | -- | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
Tango Therapeutics Inc | 42.51m | -116.49m | 747.87m | 140.00 | -- | 3.02 | -- | 17.59 | -1.11 | -1.11 | 0.4068 | 2.31 | 0.1118 | -- | -- | 303,635.70 | -30.62 | -- | -35.13 | -- | -- | -- | -274.04 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
Zenas Biopharma Inc | 50.00m | -54.76m | 748.49m | 114.00 | -- | -- | -- | 14.97 | -1.38 | -1.38 | 1.26 | 4.04 | -- | -- | -- | 595,238.10 | -- | -- | -- | -- | -- | -- | -109.51 | -- | -- | -- | 0.00 | -- | -- | -- | 68.88 | -- | -- | -- |
MBX Biosciences Inc | 0.00 | -47.20m | 756.53m | 36.00 | -- | -- | -- | -- | -1.48 | -1.48 | 0.00 | 1.71 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.60 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Suvretta Capital Management LLCas of 17 May 2024 | 13.77m | 5.30% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 6.35m | 2.45% |
Armistice Capital LLCas of 31 Mar 2024 | 6.17m | 2.38% |
Invus Public Equities Advisors LLCas of 31 Mar 2024 | 4.72m | 1.82% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 4.27m | 1.64% |
Prosight Management LPas of 31 Mar 2024 | 3.66m | 1.41% |
Geode Capital Management LLCas of 30 Jun 2024 | 3.31m | 1.28% |
PFM Health Sciences LPas of 31 Mar 2024 | 2.54m | 0.98% |
Sio Capital Management LLCas of 31 Mar 2024 | 2.43m | 0.93% |
Schroder Investment Management Ltd.as of 31 Mar 2024 | 1.93m | 0.74% |